•      The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable safety profile

Allschwil, Switzerland – March 3, 2021
Idorsia Ltd (SIX: IDIA) today announced the submission of a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for daridorexant, Idorsia's investigational dual orexin receptor antagonist, for the treatment of adult patients with insomnia.

Insomnia is a common problem with up to 10% of adults having all the symptoms that meet the diagnostic criteria for insomnia disorder. Insomnia, a condition of overactive wake signaling, is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep.

Jean-Paul Clozel MD and Chief Executive Officer of Idorsia commented:
“This European application, following the submission in the US, is an indication of our commitment to transform the treatment of insomnia around the globe. Europe has a high prevalence of insomnia and significant unmet need as the field has not benefited from innovation for many years. Most of the current treatment options are acting on the brain in a non-specific way, with restrictions due to safety concerns. This is the first European marketing application for a dual orexin receptor antagonist and, if approved, daridorexant would be the first insomnia treatment acting by a novel mechanism in decades.”

The MAA includes data from a comprehensive clinical and non-clinical development program. In the Phase 3 registration program, daridorexant showed statistically significant and clinically meaningful improvements not only in sleep duration, but also in patient-perceived sleep quantity and quality, and, for the first time for an insomnia treatment, an improvement in daytime functioning, which were sustained over time.

The Phase 3 program provided a deep understanding of the safety and tolerability profile of daridorexant. Adverse reactions reported with a frequency of ≥ 2% in daridorexant-treated patients and greater (≥ 1%) than in placebo-treated patients in 3-month efficacy trials were headache, somnolence, fatigue, dizziness, and nausea. Patients reported no next-morning sleepiness compared to placebo as assessed by the morning visual analogue scale (VAS). The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo.

These results make daridorexant the first sleep medication to demonstrate an improvement in sleep and daytime functioning, as measured by a newly developed and validated instrument, while keeping a favorable safety profile in adult and elderly patients.

In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia. More details and commentary can be found in the dedicated press releases (first study release), (second study release) and the investor webcasts (first study webcast), (second study webcast) which are available for replay on Idorsia’s corporate website: www.idorsia.com

The NDA was submitted to the US FDA on January 8, 2021. Should approval be received, the company anticipates launch in the US in the first half of 2022.

Notes to the editor

About the orexin system
Wake and sleep signaling is regulated by intricate neural circuitry in the brain. One key component of this process is the orexin system, which helps promote wakefulness. There are two forms of orexin neuropeptides – small protein-like molecules used by nerve cells (neurons) to communicate with each other in the brain – orexin A and orexin B. Orexin promotes wakefulness through its receptors OX1R and OX2R. Together, these neuropeptides and receptors make up the orexin system. The orexin system stimulates targeted neurons in the wake system – leading to the release of several chemicals (dopamine, serotonin, histamine, acetylcholine, norepinephrine) which promote wakefulness. Under normal circumstances, orexin levels rise throughout the day as wakefulness is promoted and then fall at night. Overactivity of the wake system is an important driver of insomnia.

Dual orexin receptor antagonists (DORAs) offer an entirely different approach to treating insomnia than previous drug classes: by blocking the activity of orexin, they turn down overactive wakefulness, in contrast to insomnia treatments which act via general CNS sedation. DORAs specifically target the orexin system by competitively binding with both receptors, thereby reversibly blocking the activity of orexin. Blocking orexin receptors reduces the downstream activity of the wake-promoting neurotransmitters that are overactive in insomnia. As a result, orexin receptor antagonism targets the fundamental mechanism of insomnia.

About daridorexant
Daridorexant is a dual orexin receptor antagonist (DORA) designed and developed for the treatment of insomnia. Daridorexant reduces overactive wakefulness associated with insomnia by blocking the activity of orexin. Idorsia’s research team has designed daridorexant to have a rapid onset of effect and a duration of action sufficient to cover the night but short enough to avoid any negative next-morning residual activity at optimally effective doses.

About the registration program
The Phase 3 registration program comprised two three-month studies, together with a long-term double-blind extension study. Both pivotal studies are complete, having enrolled around 1,850 patients with insomnia at over 160 sites across 18 countries. As insomnia often presents later in life, and elderly patients are more susceptible to fragmented sleep, early awakening and daytime sleepiness, around 40% of the recruited population was aged 65 years or older. The placebo-controlled studies investigated the effects of three doses of daridorexant (10 mg, 25 mg, and 50 mg) on sleep and daytime functioning parameters, objectively in a sleep lab by polysomnography and subjectively with a daily patient diary at home. The impact of insomnia on patients’ daytime functioning was measured daily using the sleepiness domain score from the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) – a patient-reported outcome (PRO) instrument validated according to FDA industry guidance.

More than 800 patients continued treatment in the ongoing 40‑week extension study, which will measure the effects of all three doses vs placebo, generating data for long-term treatment of insomnia.

The Phase 3 registration program demonstrated statistically significant and clinically meaningful improvements in sleep and daytime functioning which were sustained over time. The results showed efficacy during the night and the day, in respect of sleep maintenance, sleep onset, total sleep time and daytime functioning. The nighttime symptoms were improved while preserving the proportions of sleep stages.

The highest (50 mg) dose was the most effective, followed by 25 mg, while the 10 mg dose had only a marginal effect. A key consideration in the treatment of insomnia is the reversal of daytime functioning impairment associated with sleep difficulties – altered mood, cognition, and tiredness. To date, no insomnia studies have reported on the effects of pharmacological intervention on daytime functioning using an adequately developed and validated PRO instrument. At 50 mg, daridorexant produced consistent and meaningful improvements in scores for daytime functioning across all IDSIQ domains. Patients on daridorexant felt more energetic and less sleepy, and reported better alertness, cognition and mood.

Daridorexant was well tolerated and had a favorable safety profile in adult and elderly patients. Adverse reactions reported with a frequency of ≥ 2% in daridorexant-treated patients and greater (≥ 1%) than in placebo-treated patients in 3-month efficacy trials were headache, somnolence, fatigue, dizziness, and nausea. There was no excess of morning sleepiness, as assessed by the morning visual analogue scale (VAS), even at 50 mg. The incidence of somnolence was low and did not increase with daridorexant 50 mg compared to placebo. The incidence of adverse events of special interest, considering the potential association of orexin deficiency with narcolepsy, was low, with isolated cases of sleep paralysis or hallucinations in the daridorexant treatment groups.

About insomnia
Insomnia is defined as a combination of dissatisfaction with sleep and a significant negative impact on daytime functioning. Dissatisfaction with sleep refers to the difficulty to initiate and/or maintain sleep on at least three nights per week for at least three months, despite adequate opportunity to sleep.

Insomnia is a condition of overactive wake signaling and studies have shown that areas of the brain associated with wakefulness remain more active during sleep in patients with insomnia.

Insomnia is a common problem with a prevalence of approximately 10%. On this basis, and assuming a US adult population of around 250 million, there are approximately 25 million adults in the US who suffer from insomnia.

Insomnia as a disorder is quite different from a brief period of poor sleep, and it can take its toll on both physical and mental health. It is a persistent condition with a negative impact on daytime functioning. Idorsia’s research has shown that poor-quality sleep can affect many aspects of daily life, including the ability to concentrate, mood, and energy levels.

The goal of treatments for insomnia is to improve sleep quality and quantity, as well as daytime functioning, while avoiding adverse events and next-morning residual effects. Current recommended treatment of insomnia includes sleep hygiene recommendations, cognitive behavioral therapy and pharmacotherapy.

Key literature

• Dauvilliers, Y., et al. Ann Neurol. 2020;87(3): 347-356.
• Muehlan, C., et al. J Clin Psychopharmacol. 2020;40(2): 157-166.
• Muehlan, C., et al. J Psychopharmacol. 2020;34(3): 326-335.
• Wardle-Pinkston S, et al. Sleep Med Rev.2019;48:101205.
• Altinas HK, et al. Int J Nurs Pract. 2019;25(5):e12766.
• Boof, M. L., et al. Eur J Clin Pharmacol. 2019;75(2): 195-205.
• Muehlan, C., et al. Curr Drug Metab. 2019;20(4): 254-265.
• Muehlan, C., et al. Eur Neuropsychopharmacol. 2019;29(7): 847-857.
• Muehlan, C., et al. Clin Pharmacol Ther. 2018;104(5): 1022-1029.
• Wang C, et al. Front Mol Neurosci. 2018;11:220.
• Olfson M, et al. J Clin Psychiatry. 2018;79(5):17m12020.
• Purves D, et al. Chapter 28. In: Neuroscience. 6th ed. Sunderland, MA; Oxford University Press; 2018.
• Treiber A, et al. J Pharmacol Exp Ther. 2017;362(3):489-503.
• Kryger M, et al, eds. Principles and Practice of Sleep Medicine. 6th ed. Philadelphia, PA: Elsevier; 2017.
• Levenson JC, et al. Chest. 2015;147(4):1179-1192.
• The Diagnostic and Statistical Manual of Mental Disorders (5th ed.; DSM–5; American Psychiatric Association, 2013).
• Buysse DJ, et al. Drug Discov Today Dis Models. 2011;8(4):129-137.
• Walsh JK, et al. Sleep. 2011;34(8):997-1101.
• Brisbare-Roch, C., et al. Nat Med. 2007;13(2): 150-5.
• Nofzinger EA, et al. Am J Psychiatry. 2004;161(11):2126-2128.
• Ohayon, Sleep Medicine Reviews 6(2002)

About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 900 highly qualified specialists dedicated to realizing our ambitious targets.

For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Attachment

• Press Release PDF